Literature DB >> 24403096

Patients' experience and perception of hospital-treated Clostridium difficile infections: a qualitative study.

Isabelle Guillemin1, Alexia Marrel, Jérémy Lambert, Axelle Beriot-Mathiot, Carole Doucet, Odysseas Kazoglou, Christine Luxemburger, Camille Reygrobellet, Benoit Arnould.   

Abstract

BACKGROUND: Clostridium difficile is the leading cause of antibiotic-associated diarrhea and an important source of nosocomial infection. Clinical manifestations can range from mild diarrhea to lethal pseudomembranous colitis. Little is known about the burden of C. difficile infections (CDI) in patients.
OBJECTIVE: This qualitative study explored the impact of hospital-treated CDI on patients' lives from the first occurrence of CDI symptoms, through their hospital stay, and after discharge.
METHODS: Semi-structured interviews with 12 US and 12 French patients who had experienced CDI were conducted using an interview guide that was developed on the basis of a thorough literature review. Transcripts from these interviews were analyzed to identify concepts related to the research question.
FINDINGS: CDI affected numerous aspects of patients' lives. Patients reported that the continuous, watery, and uncontrollable diarrhea characteristic of CDI had the most impact on their daily lives. Diarrhea prevented them from participating in usual daily activities; this caused the collapse of their social lives. Patients felt humiliated and embarrassed. Patients' emotional distress worsened once hospitalized; they reported feelings of loneliness and worry when placed in isolation. From discharge to the time of the interview, patients reported both psychological and physical improvement. However, despite continuing improvement, most patients reported persistent worry and fear of recurrent episodes, and they were thus more careful about their diet and hygiene.
CONCLUSION: As one patient in this study explained, CDI is "the worst of everything that I've had." The emotional distress and extreme physical exhaustion associated with CDI result in a traumatic and frightening experience for patients. This trauma persists after recovery and includes lingering fears of a recurrent episode.

Entities:  

Mesh:

Year:  2014        PMID: 24403096     DOI: 10.1007/s40271-013-0043-y

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  22 in total

1.  The impact of strict isolation on MRSA positive patients: an action-based study undertaken in a rehabilitation center.

Authors:  Kristine L Webber; Sherry Macpherson; Angela Meagher; Susan Hutchinson; Blair Lewis
Journal:  Rehabil Nurs       Date:  2012 Jan-Feb       Impact factor: 1.625

2.  Psychological impact of short-term isolation measures in hospitalised patients.

Authors:  M W M Wassenberg; D Severs; M J M Bonten
Journal:  J Hosp Infect       Date:  2010-04-10       Impact factor: 3.926

3.  Sample size in qualitative research.

Authors:  M Sandelowski
Journal:  Res Nurs Health       Date:  1995-04       Impact factor: 2.228

Review 4.  The changing epidemiology of Clostridium difficile infections.

Authors:  J Freeman; M P Bauer; S D Baines; J Corver; W N Fawley; B Goorhuis; E J Kuijper; M H Wilcox
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

Review 5.  Clostridium difficile: development of a novel candidate vaccine.

Authors:  Ginamarie Foglia; Siddhi Shah; Christine Luxemburger; Patricia J Freda Pietrobon
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

6.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

7.  Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy.

Authors:  C McNulty; M Logan; I P Donald; D Ennis; D Taylor; R N Baldwin; M Bannerjee; K A Cartwright
Journal:  J Antimicrob Chemother       Date:  1997-11       Impact factor: 5.790

8.  Contact isolation for infection control in hospitalized patients: is patient satisfaction affected?

Authors:  Leanne B Gasink; Karyn Singer; Neil O Fishman; William C Holmes; Mark G Weiner; Warren B Bilker; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2008-03       Impact factor: 3.254

9.  Functioning and health in patients with cancer on home-parenteral nutrition: a qualitative study.

Authors:  Martin Mueller; Stefanie Lohmann; Paul Thul; Arved Weimann; Eva Grill
Journal:  Health Qual Life Outcomes       Date:  2010-04-16       Impact factor: 3.186

Review 10.  Adverse outcomes associated with Contact Precautions: a review of the literature.

Authors:  Daniel J Morgan; Daniel J Diekema; Kent Sepkowitz; Eli N Perencevich
Journal:  Am J Infect Control       Date:  2009-03       Impact factor: 2.918

View more
  4 in total

1.  Health-related quality of life in patients with recurrent Clostridioides difficile infections.

Authors:  Lianna H Hammeken; Simon M D Baunwall; Jens F Dahlerup; Christian L Hvas; Lars H Ehlers
Journal:  Therap Adv Gastroenterol       Date:  2022-04-18       Impact factor: 4.802

2.  Patient Perspectives on Fecal Microbiota Transplantation for Clostridium Difficile Infection.

Authors:  Caroline Zellmer; Travis J De Wolfe; Sarah Van Hoof; Rebekah Blakney; Nasia Safdar
Journal:  Infect Dis Ther       Date:  2016-04-05

Review 3.  Novel Antimicrobials for the Treatment of Clostridium difficile Infection.

Authors:  Nicola Petrosillo; Guido Granata; Maria Adriana Cataldo
Journal:  Front Med (Lausanne)       Date:  2018-04-16

4.  Fecal Microbiota Transplants Annually and Their Positive Clinical Impact.

Authors:  Lamia Mamoon; Scott W Olesen
Journal:  Clin Transl Gastroenterol       Date:  2020-11       Impact factor: 4.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.